David Guyer

Chairman of the Board

David Guyer, M.D., joined SV Life Sciences in 2006 and serves on the boards of portfolio companies Link Medicine, Lux Biosciences, NeoVista, Neurotech and Ophthotech as well as the public company Optos. David co-founded and served as CEO and director of Eyetech Pharmaceuticals Inc. for six years. He led Eyetech - a biopharmaceutical company that specialized in the development and commercialization of novel therapeutics to treat diseases of the eye - through private financing rounds totaling approximately $170 million, a $157 million initial public offering and a secondary financing. The company developed and gained FDA approval for Macugen, the first anti-VEGF treatment approved for macular degeneration. Eyetech partnered with Pfizer in a deal valued at over $750 million. OSI Pharmaceuticals subsequently acquired Eyetech in a deal valued at $935 million. Prior to founding Eyetech, Dr. Guyer was professor and chairman of the department of ophthalmology at the NYU School of Medicine. Dr. Guyer holds a BSc from Yale College and a medical degree from Johns Hopkins Medical School.

Paul Chaney

President and Chief Executive Officer

Paul Chaney is president and CEO of PanOptica, Inc., a start-up, venture-backed private biopharma company, with a mission to develop innovative ophthalmic therapeutics. Prior to co-founding PanOptica, Paul was executive vice president of OSI Pharmaceuticals and president of (OSI) Eyetech, OSI’s eyecare subsidiary. He joined Eyetech Pharmaceuticals as chief operating officer in 2003. Paul has nearly 30 years of experience in the pharmaceutical industry, including a variety of senior management positions at Pharmacia Corporation. At Pharmacia, Paul served as vice president of the Global Ophthalmology Business and as vice president of Global Pharmaceutical Ophthalmology. He began his career as a sales representative for The Upjohn Company in 1980. Paul earned a dual degree in Biological Sciences and English from the University of Delaware.

Colin Goddard, Ph.D.

Member, Board of Directors

Colin Goddard, Ph.D., served as chief executive officer of OSI Pharmaceuticals from 1998 until the company’s $4 billion acquisition by Astellas Pharmaceuticals, Inc. in June of 2010. Dr. Goddard joined OSI as a scientist in 1989, and advanced through the ranks as director of drug discovery and pharmaceutical operations, vice president of research operations, executive vice president and chief operating officer, and president until he was named CEO. Dr. Goddard led the approval and launch of OSI's lead product, the cancer drug Tarceva®(erlotinib). He currently sits on the Board of Trustees at Hofstra University and is a Director of Human Genome Sciences, Inc., Zelos Therapeutics, Inc., and Abilities!, a leading charity for the physically disabled

Tracy Saxton, Ph.D.

Member, Board of Directors

Tracy Saxton is an Investment Professional with SV Life Sciences based in San Francisco. Dr. Saxton currently works with the teams at Catabasis Pharmaceuticals, Rempex Pharmaceuticals, Cyterix Pharmaceuticals and Arsanis Biosciences. Before joining SVLS, Tracy was at Mission Bay Capital, a University of California-affiliated seed-stage venture capital firm based in San Francisco. Previously, Tracy held positions in drug discovery, regulatory affairs and program management at Tularik/Amgen, Threshold Pharmaceuticals, and Geron Corp. She was Project Leader for development programs in HIV/immunotherapy, urology, and oncology, spanning preclinical through Phase 3 of development. Tracy earned her PhD in Molecular Genetics from the University of Toronto, her MBA from Columbia Business School and her a BSc (Biology) from Simon Fraser University. Tracy was a Damon Runyon-Walter Winchell Cancer Fund fellow at UCSF and is also a Kauffman Fellow.

Kevin Starr

Member, Board of Directors

Kevin Starr is a proven operational leader with over 25 years’ experience building and operating leading biotech companies. Mr. Starr co-founded Third Rock Ventures in 2007 and focuses on the formation, development and business strategy of its portfolio companies as well as actively identifying and evaluating new investments. He also assumes active leadership roles in Third Rock portfolio companies. Prior to Third Rock Ventures, Mr. Starr was chief operating officer and chief financial officer at Millennium Pharmaceuticals, where he led efforts to raise billions of dollars in capital through strategic alliances and public financing and drove growth through company expansion and mergers and acquisitions. Earlier in his career, he served in various executive roles at Millennium BioTherapeutics, Biogen and Digital Equipment Corporation. Mr. Starr holds an M.S. in corporate finance from Boston College and a B.A. in mathematics and business from Colby College. He is a Board Member of Alnylam Pharmaceuticals and also serves on the Board of Directors for Afferent Pharmaceuticals, Agios Pharmaceuticals and Zafgen, Inc.